Biotechnology Press Release
|05/11/2020 - 07:46||
BioMarin Announces Proposed Private Offering of $500 Million of Senior Subordinated Convertible Notes
BioMarin also intends to grant the initial purchasers of the notes a 13-day option to purchase up to an additional $50.0 million aggregate principal amount of notes.
|05/11/2020 - 07:33||
Ampio Reports Acceptance of Publication on the Potential Benefits of Nebulized Ampion for COVID-19 Patients
The manuscript titled, “The novel immunomodulatory biologic LMWF5A (Ampion) for pharmacological attenuation of the “cytokine storm” in COVID-19 patients: a hypothesis”, provides a detailed description of the biochemical and immunological phenomena collectively termed the “cytokine storm” encountered in COVID-19 patients and evaluates the potential benefit of Ampion treatment for these patients. A link to the publication will be provided on the company’s website once available.
|05/11/2020 - 06:11||
BioMarin Announces Pricing of Upsized $550 Million Senior Subordinated Convertible Notes Offering
The aggregate principal amount of the offering was increased from the previously announced offering size of $500.0 million. BioMarin also granted the initial purchasers of the notes a 13-day option to purchase up to an additional $50.0 million aggregate principal amount of notes. The sale of the notes is expected to close on May 14, 2020, subject to customary closing conditions.
|05/11/2020 - 02:41||
Automotive Wiring Harness Market Report 2020, Covid-19 Impact, Market Trends, Share, Size & Forecast Till 2025
According to the latest report by IMARC Group titled, “Automotive Wiring Harness Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025”, the global automotive wiring harness market grew at a CAGR of around 6% during 2014-2019.
|05/09/2020 - 19:33||
Coronavirus (COVID-19) Update: FDA Authorizes First Antigen Test to Help in the Rapid Detection of the Virus that Causes COVID-19 in Patients
The U.S. Food and Drug Administration has issued the first emergency use authorization (EUA) for a COVID-19 antigen test, a new category of tests for use in the ongoing pandemic. These diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs.
|05/08/2020 - 13:47||
Reopening America, China's 'Mask Diplomacy,' State Police Powers: RAND Weekly Recap
This week we discuss a new RAND tool that estimates the effects of rolling back or maintaining social distancing and other disease-fighting measures; how China is trying to distract from its role in the pandemic; state police powers and COVID-19; protecting food workers and volunteers; the looming rental housing crisis; and using rideshares to provide non-emergency medical transportation.
|05/08/2020 - 13:01||
From astronaut to economist, the Alltech ONE Virtual Experience announces stellar keynote lineup
The Alltech ONE Virtual Experience will offer on-demand insights from leading experts in agriculture and beyond, beginning May 18, 2020.
|05/08/2020 - 09:57||
Scottish funding supports Roslin Covid-19 work
Research on the transmission of the coronavirus, critical aspects of the disease and 3D printing of bespoke PPE receive Scottish Government funding.
|05/08/2020 - 09:47||
Lupins Pithampur Facilities Complete Successful UK MHRA Inspection
Mumbai, India, May 8, 2020: Pharma major Lupin Limited (Lupin) today announced the successful close out of the inspection carried out by the Medicines and Healthcare products Regulatory Agency (MHRA), the regulatory agency of the United Kingdom (UK), at its three manufacturing units in Pithampur (India). The inspection for the three units at Pithampur (Unit I, Unit II and Unit III) was conducted in January 2020.
|05/08/2020 - 08:31||
Data method seeks weak spots in coronavirus DNA
Machine learning algorithms can identify areas of coronavirus genetic makeup that could be the focus of potential treatments.
|05/08/2020 - 01:19||
Sorrento And Mount Sinai Health System To Jointly Develop COVI-SHIELD Antibody Therapy Targeting SARS-CoV-2 Infection (COVID-19)
Carlos Cordon-Cardo , MD, PhD, Irene Heinz Given and John LaPorte Given Professor and Chair of Pathology, Molecular and Cell-Based Medicine at the Icahn School of Medicine at Mount Sinai and his team screened approximately fifteen thousand individuals who may have had and recovered from COVID-19 for the presence of anti-COVID-19 antibodies.
|05/08/2020 - 00:12||
GlycoMimetics Announces Change to Virtual Meeting Format for 2020 Annual Meeting of Shareholders
Due to the ongoing public health impact of the COVID-19 pandemic and to support the health and well-being of the Company’s stockholders, employees and their families, the Company will hold the Annual Meeting via live audio webcast rather than as an in-person meeting. The virtual Annual Meeting is expected to provide stockholders with the same rights and opportunities to participate as they would have at an in-person meeting. As previously announced, the Annual Meeting will be held on Friday, May 22, 2020 at 9:00 a.m.
|05/07/2020 - 15:57||
ANU Socially Responsible Investment Report 2019
The Australian National University adopted a Socially Responsible Investment (SRI) Policy in July 2013. This policy contained clear Environmental, Social and Governance (ESG) benchmarks, becoming at the time one of only a handful of Universities worldwide who use responsible investment to advance its objectives on social and sustainability issues.
|05/07/2020 - 15:24||
Scientists at Gladstone and UCSF launch new efforts in virology and genomic immunology
Gladstone Celebrates is an event held annually to recognize individuals who have made extraordinary contributions to Gladstone’s community and outstanding scientific achievements.
|05/07/2020 - 11:56||
Research Brief: Ethics around businesses marketing unproven and unlicensed COVID-19 stem-cell-based therapies
A scientist doing a cell culture experiment in a cleanroom facility. Photo credit: Manjurul on Getty Images.
|05/07/2020 - 11:54||
BIOCLINICA ANNOUNCES COMPREHENSIVE COVID-19 CLINICAL ENDPOINT ADJUDICATION SOLUTION
PRINCETON, N.J., May 7, 2020 – Bioclinica, a leading provider of clinical science and technology expertise to assist the life science industry, today announced a specialized program for the adjudication of adverse events that could result from COVID-19 infection.
|05/07/2020 - 10:32||
Applied BioMath, LLC Provides Systems Pharmacology Model to Support Fibrinolytic Therapy for Refractory COVID-19 Acute Respiratory Distress Syndrome
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced that it is creating a systems pharmacology model to support ongoing research into the compassionate care use of tissue plasminogen activator (tPA) as treatment of respiratory distress for patients with Acute Respiratory Distress Syndrome (ARDS) due to COVID-19, for whom ventilators do not work, or for those without ventilators.
|05/07/2020 - 10:22||
CoVIg-19 Plasma Alliance Builds Strong Momentum Through Expanded Membership and Clinical Trial Collaboration
Osaka, JAPAN, and King of Prussia, PA, USA - Rapidly expanding support for the Alliance is increasing donations of convalescent plasma to begin clinical production, while NIH collaboration confirms clinical trial approach - Alliance urges anyone who has recovered from COVID-19 to consider donating today.
|05/07/2020 - 10:12||
SELLAS to Present at UBS Virtual Global Healthcare Conference
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that Angelos Stergiou, M.D., ScD h.c., President and Chief Executive Officer of SELLAS, will present a corporate overview at the UBS Virtual Global Healthcare Conference on Monday, May 18, 2020 at 4:40 pm EDT (1:40 pm PDT).
|SELLAS Life Sciences|
|05/07/2020 - 09:13||
Research Brief: Engineering natural selection in microbes has implications for biofuel production, addressing antibiotic resistance
Scientists who study adaptation — or edit the genes of organisms — know the limitations inherent in conventional approaches to mutation that offer little opportunity to target individual genes without altering others as well.
|05/07/2020 - 08:53||
JAX, UConn Health partnering to train the next generation of genomic scientists
JAX delivers hands-on and immersive educational programs in Maine, Connecticut and across the globe. Sign up for event updates and information.
|05/07/2020 - 08:05||
Roslin broadens research tackling Covid-19
Roslin work includes investigating the coronavirus impact, origin, treatment pathways and tracking Covid-19.
|05/07/2020 - 07:09||
OPTI Medical Systems Receives US FDA Emergency Use Authorization for Its OPTI SARS-CoV-2 RNA PCR Test Kit for Detection of the Virus Causing COVID-19
ROSWELL, Ga., and WESTBROOK, Maine, May 7, 2020—OPTI Medical Systems, Inc., a subsidiary of IDEXX Laboratories, Inc.
|05/07/2020 - 06:41||
Thermo Fisher Scientific Announces SARS-CoV-2 GlobalAccess Sequencing Program
Company to provide 50 Ion Torrent Genexus Systems for consortia members at a subsidized price to support global COVID-19 research.
|Thermo Fisher S...|
|05/07/2020 - 03:06||
Quadram researchers working on COVID-19 vaccine join WHO expert groups
Quadram Institute researchers who are working on a new drug delivery method for a COVID-19 vaccine have joined World Health Organization (WHO) expert advisory groups tackling the coronavirus.